KRAKOW, Poland, May 13,
2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical
stage drug discovery and development company engaged in the
research and development of novel cancer therapies, today announced
that the company will present at the UBS Global Healthcare
Conference, taking place on May 20-22
in New York. Chief Executive
Officer Pawel Przewiezlikowski is
scheduled to present a corporate overview on Tuesday, May 21 at 3:30
p.m. EDT.
Selvita will be also present at Jefferies 2019 Healthcare
Conference, taking place on June 4-7, in New York, NY, USA.
About Selvita
Selvita is developing novel small molecule therapies that
address emerging targets in oncology with industry-leading research
expertise supported by a research services division. Pipeline
candidates apply diverse mechanisms directed at kinases, synthetic
lethality pathways, immuno-oncology pathways and other
cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase
inhibitor licensed to the Menarini Group in clinical development
for the treatment of acute myeloid leukemia. SEL120 is a CDK8
kinase inhibitor with potential for development in indications
including hematological malignancies and solid tumors. Selvita is
headquartered in Krakow with
offices in the U.S. and U.K. In March
2019, Selvita announced the intent to split its oncology
development and research services divisions into separate
companies.
Contact:
Julia Balanova (investors)
+1 646 378 2936
jbalanova@troutgroup.com
Rich Allan (media)
+1 646 378 2958
rallan@troutgroup.com
Natalia Baranowska
(corporate)
+48 784 069 418
natalia.baranowska@selvita.com
View original
content:http://www.prnewswire.com/news-releases/selvita-to-present-at-the-ubs-2019-global-healthcare-conference-in-new-york-300848688.html
SOURCE Selvita